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bjective: Asthma is a chronic inﬂammatory disorder of the airways with increasing worldwide prevalence.
espite treatment according to guidelines, a considerable proportion of patients with asthma remain
ymptomatic. Different potential therapeutic options for the treatment of these patients are currently in
evelopment and undergoing clinical trials, and it is important to regularly review their status.
Data Sources: A search of ClinicalTrials.gov was performed and supported by a PubMed literature search and
restricted to the previous 10 years to ensure currency of data. The results were manually ﬁltered to identify
relevant articles.
Study Selections: Emerging therapies that are currently in phase 2 and 3 development include anti-
interleukin agents (benralizumab, reslizumab, dupilumab, brodalumab, lebrikizumab, and mepolizumab),
a chemoattractant receptor-homologous molecule expressed on a T-helper type 2 lymphocyte antagonist
(OC000459), a phosphodiesterase-4 inhibitor (roﬂumilast), and long-acting muscarinic antagonists (glyco-
pyrronium bromide, umeclidinium bromide, and tiotropium bromide).
Results: The clinical trial program of the long-acting muscarinic antagonist tiotropium is currently the most
advanced, with data available from different phase 2 and 3 studies. Results demonstrate that it is an efﬁca-
cious add-on to at least inhaled corticosteroid maintenance therapy across severities of symptomatic asthma.
Conclusion: The results of ongoing and future studies will help to determine whether these emerging
therapeutic options will help address the unmet need for improvement in asthma management.
 2015 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction asthma remain symptomatic.3e6 In the United States, the AsthmaAsthma is an inﬂammatory disease of the airways, with multi-
factorial pathophysiology. It is one of the most common chronic
conditions, with a global prevalence of up to 18%, and is expected to
affect approximately 400 million people worldwide by 2025.1 Cur-
rent Global Initiative for Asthma guidelines recommend stepwise
treatment to achieve and maintain asthma control.2 After initial
treatment with inhaled corticosteroids (ICS), an increase in the
ICS dose or the addition of another controller therapy, including
long-acting b2-agonists (LABAs), leukotriene modiﬁers, or theoph-
ylline, is recommended to achieve control. In patients with more
severe disease where control cannot be achieved add-on therapy
with anti-immunoglobulin E or oral glucocorticosteroids is
recommended.
Despite treatment according to current guidelines, such as the
Global Initiative for Asthma guidelines, at least 40% of patients withniversity, Firestone Institute for
thcare, 50 Charlton Avenue East,
ivor@stjosham.on.ca.
aria and grants from Boehringer
sthma & Immunology. Published by EControl Characteristics and Prevalence Survey Studies reported un-
controlled asthma in 58.8% and 49.7% of adult and pediatric patients,
respectively,7 whereas the European REcognise Asthma and LInk to
SymptomsandExperiencesurvey reporteduncontrolledasthma in45%
of respondents.8 Poorlycontrolled asthmaputs patients at risk of future
exacerbations and thus has a signiﬁcant impact on patients’ lifestyles
and on the use of health care resources and health care costs.9e13 It is
important to recognize that although the degree to which a patient’s
asthma is controlledmightbe related todisease treatmentor severity, it
also might be affected by different variables, including comorbidities
such as allergic rhinitis and gastroesophageal reﬂux, poor treatment
adherence, incorrect inhaler technique, allergen exposure, or concur-
rent smoking.14
There is an ongoing need for improvements in the management
and control of asthma. This review examines recently published
clinical data on emerging therapeutic options for the treatment of
patients with symptomatic asthma.Emerging Therapeutic Options for the Treatment of Asthma
Different promising therapeutic options are currently
in development and undergoing clinical trials for thelsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
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(IL) agents, chemoattractant receptor-homologous molecules
expressed on T-helper type 2 lymphocyte (CRTH2) antagonists,
phosphodiesterase-4 inhibitors, and long-acting muscarinic
antagonists (LAMAs). The emerging anti-IL agents benralizumab,
reslizumab, dupilumab, brodalumab, lebrikizumab, and mepoli-
zumab, the CRTH2 antagonist OC000459, the phosphodiesterase-
4 inhibitor roﬂumilast, and the LAMAs glycopyrronium bromide,
umeclidinium bromide, and tiotropium bromide were identiﬁed
for inclusion based on recent literature.
Search Strategy
AsearchofClinicalTrials.govwasperformedusing thedrugnames
listed earlier AND asthma as search terms (Table 1). A PubMed liter-
ature search also was performed using the Boolean string asthma*
[title/abstract] AND drug name [title/abstract] AND clinical trial [ptyp]
andwas restricted to the previous 10 years to ensure currencyof data
(June 2015). The results were manually ﬁltered to identify relevant
articles or studies with data fromwell-designed clinical trials of the
treatment of interest in human patients.
Anti-IL Agents in the Treatment of Asthma
Anti-IL agents are monoclonal anticytokine agents that decrease
airway inﬂammation and prevent eosinophil activation.15,16 The
literature search provided 16 publications relating to the anti-IL
agents benralizumab, reslizumab, dupilumab, brodalumab, leb-
rikizumab, and mepolizumab (eTable 1A).
Benralizumab
An initial phase 1 study in 27 patients with asthma found that
single-dose intravenous and multiple-dose subcutaneous benrali-
zumab (antieIL-5) decreased airway, bone marrow, and peripheral
blood eosinophil counts, with comparable safety proﬁles.17 In a
phase 2 study in 108 patients with acute asthma, a single dose of
intravenous benralizumab was found to decrease the rate (1.82 vs
3.59 [total number of exacerbations per total duration of person-
year follow-up], P ¼ .01) and severity (0.65 vs 1.62 [total number
of exacerbations per total duration of person-year follow-up], P ¼
.02) of asthma exacerbations compared with placebo and had an
acceptable safety proﬁle.18 Patients with severe asthma are
currently being recruited for additional phase 3 studies (Table 1).
Reslizumab
In a study of 106 patients with severe eosinophilic asthma,
treatment with monthly reslizumab infusions (antieIL-5) showed aTable 1
Summary of emerging therapeutic options in the treatment of asthma, listed on Clinical
Therapeutic class Mode of
administration
Mechanism of action
Anti-interleukin agents injection anti-inﬂammatory
CRTH2 antagonists oral anti-inﬂammatory
Phosphodiesterase-4 inhibitors oral anti-inﬂammatory
Long-acting muscarinic antagonists oral bronchodilator
Abbreviation: CRTH2, chemoattractant receptor-homologous molecules expressed on T-htrend toward improved asthma control (P ¼ .0541), signiﬁcantly
decreased sputum eosinophils (P ¼ .0068), and signiﬁcantly
improved lung function, as measured by forced expiratory volume
in 1 second (FEV1; P ¼ .0023), percentage of predicted FEV1 (P ¼
.0010), and forced vital capacity (FVC; P ¼ .0054), compared with
placebo.15 The results from the ﬁrst phase 3 trials in 953 adult and
adolescent patients (489 patients in study 1 and 464 patients in
study 2) with moderate to severe eosinophilic asthma
(NCT01287039 and NCT01285323) showed that monthly intrave-
nous reslizumab signiﬁcantly decreased the frequency of asthma
exacerbations (P < .0001 in the 2 trials) and had a similar adverse-
event proﬁle compared with placebo.19 Additional phase 2 and 3
trials of reslizumab in adult and pediatric patients with eosino-
philic asthma are currently ongoing (Table 1).
Dupilumab
Dupilumab (antieIL-4) showed efﬁcacy in a 12-week phase 2
trial of 104 patients with moderate to severe eosinophilic asthma
(NCT01312961). Signiﬁcant decreases in the incidence of asthma
exacerbations (P < .001) and signiﬁcant improvements in most
measurements of lung function (FEV1, P < .001) and asthma control
(5-question Asthma Control Questionnaire [ACQ-5], P ¼ .001) were
observed after once-weekly subcutaneous administration of 300
mg of dupilumab compared with placebo; dupilumab also was
found to decrease biomarkers associated with T-helper type 2
(TH2)-driven inﬂammation.16 A phase 2 trial and follow-on phase 3
trial are currently ongoing to evaluate the efﬁcacy and safety of
different doses and treatment regimens of dupilumab in patients
with moderate to severe asthma (Table 1).
Brodalumab
In a phase 2 dose-ranging study in 302 adult patients with
moderate to severe asthma (NCT01199289), no treatment differences
were observed in 7-question ACQ (ACQ-7) scores, lung function, or
asthma symptoms after subcutaneous brodalumab (antieIL-17) at
140, 210, or 280 mg or placebo. Prespeciﬁed subgroup analyses
showed an improvement in ACQ-7 score beyond the minimal clini-
cally important difference after 210 mg of brodalumab only (P¼ .02;
no adjustment for multiplicity) in patients with high bronchodilator
reversibility (post-bronchodilator FEV1 improvement 20%).20 A
second phase 2 study of brodalumab in patients with high bron-
chodilator reversibility is currently recruiting patients (Table 1).
Lebrikizumab
Lebrikizumab (antieIL-13) at 250 mg, administered subcutane-
ously every 4 weeks, showed improved lung function in a phase 2Trials.gov
Drug name Sponsor Development
phase
benralizumab AstraZeneca 3
Kyowa Hakko Kirin Company 2
MedImmune 1/2
reslizumab Teva 2/3
GlaxoSmithKline 3
dupilumab Sanoﬁ 2/3
brodalumab Amgen 2
lebrikizumab F. Hoffmann-La Roche 2/3
Genentech 2
mepolizumab GlaxoSmithKline 2/3
OC000459 Oxagen 2
Atopix Therapeutics 1
roﬂumilast Takeda 2/3
glycopyrronium bromide Chiesi 1/2
umeclidinium bromide GlaxoSmithKline 1/2
tiotropium bromide Boehringer Ingelheim 2/3
elper type 2 lymphocytes.
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despite medium- to high-dose ICS therapy (NCT00930163). Im-
provements in FEV1 were signiﬁcant compared with placebo (P ¼
.02), with greater improvements observed in patients with high
serum-periostin levels.21 In a second phase 2 trial in 212 patients
with asthma not receiving ICS (NCT00971035), monthly subcu-
taneous administration of lebrikizumab at 125, 250, or 500 mg did
not provide any meaningful improvements in lung function.22 In a
third phase 2 trial in 29 adult patients with mild allergic asthma
(NCT00781443), monthly lebrikizumab treatment decreased the late
asthmatic response (FEV1 decrease 15% 2e12 hours after allergen
challenge) by 48% comparedwith placebo, with exploratory analyses
showing that patients with allergic asthma exhibited a greater
decrease compared with those with nonallergic asthma.23 Addi-
tional phase 2 studies of lebrikizumab in the treatment of asthma are
ongoing, with phase 3 studies currently recruiting patients (Table 1).
Mepolizumab
Studies in patients with severe eosinophilic asthma showed that
mepolizumab (antieIL-5) decreased exacerbation risk, improved
quality of life, lowered eosinophil counts, improved asthma control,
and improved lung function. In a phase 2 trial of 621 patients
(NCT01000506), treatment with intravenous mepolizumab signiﬁ-
cantly lowered the rate of clinically signiﬁcant exacerbations (48%
decrease in the 75-mg group, 39% decrease in the 250-mg group, 52%
decrease in the 750-mg group, P  .0005 for all comparisons)
comparedwith placebo.24 In a parallel-group trial of 61 patientswith
refractory eosinophilic asthma, monthly treatment with 750 mg of
intravenous mepolizumab was associated with fewer severe exac-
erbations (P ¼ .02), lower blood (P < .001) and sputum (P ¼ .002)
eosinophil counts, and signiﬁcant improvements in quality of life
(P¼ .02) over 1 year comparedwith placebo, although no signiﬁcant
improvements in asthma symptoms, FEV1, or airway hyper-
responsiveness were observed between treatment groups.25 After
cessation ofmepolizumab treatment, an increase in blood eosinophil
count, severe exacerbation frequency, and asthma symptoms was
observed.26 In a phase 2 parallel-group study of 20 patients with
corticosteroid-dependent eosinophilic asthma (NCT00292877), the
proportion of patientswho experienced an asthma exacerbationwas
signiﬁcantly decreased (P ¼ .008); there also were signiﬁcant de-
creases in sputum (P ¼ .005) and blood (P ¼ .004) eosinophil levels
and a signiﬁcant improvement in asthma control (P ¼ .01) after 750
mg of intravenous mepolizumab every 4 weeks.27 In a phase 3 study
of 576 patients with severe eosinophilic asthma (NCT01691521),
exacerbation rate was decreased by 47% and 53% and FEV1 was
increased by 100 and 98 mL (P < .05 for all comparisons) in patients
receiving 75 mg of intravenous mepolizumab and 100 mg of subcu-
taneous mepolizumab monthly, respectively, with signiﬁcant im-
provements also observed in asthma control.28 In a second phase
3 study in 135 patients with severe eosinophilic asthma, after
treatmentwith100mgof subcutaneousmepolizumabevery4weeks,
there was a 32% decrease in exacerbation rate and a decrease of 0.52
in ACQ-5 score, with the decrease in background ICS use 2.39 times
greater than in the placebo treatment group.29 Conversely, in a study
by Flood-Page et al30 of 362 patients with moderate symptomatic
asthma, no signiﬁcant clinical beneﬁt was observed in lung function,
rescue medication use, asthma symptoms, exacerbation rate, or
quality of life after 3 intravenous infusions of 250 or 750 mg of
mepolizumabatmonthly intervals. In a subsetof37patients fromthis
study, signiﬁcant decreases in sputum and blood eosinophils were
observed after treatment with 250 and 750 mg of intravenous
mepolizumab every 4 weeks (sputum, P ¼ .006 and P ¼ .004,
respectively; blood, P< .001 for the 2 doses). Several additional phase
2 and 3 studies of mepolizumab in the treatment of patients with
severe eosinophilic asthma are ongoing but have yet to report data
(Table 1).CRTH2 Antagonists in the Treatment of Asthma
The CRTH2 is a G-proteinecoupled receptor that mediates the
activationof TH2 lymphocytes, eosinophils, andbasophils in response
toprostaglandinD2.31e33AirwayprostaglandinD2 levelsareelevated
in patients with asthma after an allergen challenge, suggesting a role
in TH2-mediated allergic inﬂammation, and therefore CRTH2 antag-
onists might inhibit the activation of lymphocytes, eosinophils, and
basophils and decrease the asthma allergic response.32,33 Three
publications related to OC000459 were identiﬁed (eTable 1B), which
is currently in phase 2 development (Table 1).
OC000459
A phase 2 study of twice-daily OC000459 at 200 mg
(NCT01057927) showed signiﬁcantly improved quality of life (P ¼
.0113) and nocturnal symptoms (P ¼ .008) compared with placebo
in 132 patients with moderate persistent asthma. Improvements in
FEV1 and sputum eosinophil count alsowere observed but were not
statistically signiﬁcant.32 In a 2-way phase 2 crossover study of 21
steroid-naive patients with asthma (NCT01056692), treatment
with twice-daily OC000459 at 200 mg was found to signiﬁcantly
inhibit the late asthmatic response to allergen challenge (P ¼ .018)
and signiﬁcantly reduce the post-allergen increase in sputum eo-
sinophils (P ¼ .002); OC000459 treatment had no effect on the
early asthmatic response to allergen challenge.33 In a phase 2 dose-
ﬁnding study of OC000459 once daily at 25 or 200mg or twice daily
at 100 mg in 519 patients with mild to moderate persistent asthma
(NCT00890877), a signiﬁcant improvement in FEV1 was observed
after treatment with the once-daily 25-mg dose (P ¼ .028). Sig-
niﬁcant improvements also were observed in ACQ-7 (P ¼ .001) and
Asthma Quality of Life Questionnaire (P ¼ .002) scores, and there
was a nonsigniﬁcantly lower incidence of exacerbations and a
signiﬁcant decrease in respiratory infections (P ¼ .003), in patients
treated with OC000459 compared with placebo.31
Phosphodiesterase-4 Inhibitors in the Treatment of Asthma
Phosphodiesterases are involved in the degradation of cyclic
adenosine monophosphate, a natural modulator of inﬂammation,
which results in increased activity of inﬂammatory cells involved in
the etiology of asthma, including T lymphocytes, eosinophils,
macrophages, mast cells, monocytes, and neutrophils.34e37 Inhibi-
tion of phosphodiesterase activity results in maintenance of cyclic
adenosine monophosphate levels and subsequent downregulation
of inﬂammatory processes in cells involved in the pathophysiology
of asthma.34e36 The PubMed literature search provided 6 publica-
tions related to roﬂumilast in the treatment of asthma (eTable 1C),
with phase 2 and 3 trials ongoing (Table 1). Roﬂumilast is approved
for use in the treatment of chronic obstructive pulmonary disease,
and anti-inﬂammatory effects have been observed in patients with
asthma.36e38
Roﬂumilast
Treatment with roﬂumilast has been shown to signiﬁcantly
improve the late asthmatic response compared with placebo. In a
2-period crossover study in 13 patients with mild allergic asthma,
treatment with a single dose of 1,000 mg of roﬂumilast signiﬁcantly
improved the late asthmatic response to a histamine challenge (P¼
.005).37 A 3-period crossover study of 23 patients with mild asthma
showed that once-daily treatment with 250 or 500 mg of roﬂumilast
signiﬁcantly decreased the early (P ¼ .0110 and P ¼ .0009, respec-
tively) and late (P ¼ .0038 and P ¼ .0046, respectively) asthmatic
reactions to allergens.36 Further, in a phase 2 trial of 25 patients
with mild allergic asthma (NCT01365533), 500 mg of roﬂumilast
once daily inhibited the allergen-induced late-phase response
(maximum percentage decrease in FEV1, P ¼ .02).38
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treatment with roﬂumilast. In a double-blinded, parallel-group
trial of 693 adolescent and adult patients with mild to moderate
asthma, treatment with once-daily roﬂumilast at 100, 250, or 500
mg signiﬁcantly improved FEV1 (P < .001 for all comparisons), with
the 500-mg dose providing the greatest improvements. Morning
and evening peak expiratory ﬂow also were improved (P  .006 for
all comparisons) compared with placebo.34 In a noninferiority
study of 499 adolescent and adult patients with persistent asthma,
once-daily roﬂumilast at 500 mg was found to provide comparable
improvements in FEV1 and FVC compared with treatment with
twice-daily beclomethasone dipropionate at 200 mg.35
In addition to showing efﬁcacy in adult and adolescent patients
with asthma, roﬂumilast has shown efﬁcacy in pediatric patients
with asthma. A 2-period ascending-dose study in 13 children and
12 adolescents with mild to moderate asthma found that roﬂumi-
last was well tolerated and that pharmacokinetic parameters were
similar to those observed in adults.39
LAMAs in the Treatment of Asthma
The short-acting muscarinic antagonists ipratropium bromide and
oxitropium bromide have been used in the treatment of asthma for
several years; however, theirwidespreadusehas been limited because
they are considered less effective than short-acting b2-agonists.40
LAMAs block muscarinic acetylcholine receptors to impact on airway
tone, smooth muscle contraction, mucus secretion, and vaso-
dilation.40e43 LAMAshave not been thoroughly investigated in asthma
because of the perception that they provide little bronchodilation
above that induced by LABAs.44,45 This view has now changed, and
some LAMAs are being investigated in clinical trials of asthma,
including glycopyrrolate, umeclidinium, and tiotropium46,47 (Table 1).
A small phase 3 crossover study in 10 patients with asthma
demonstrated that glycopyrrolate signiﬁcantly prolonged bron-
chodilatation and bronchoprotection compared with ipratropium
(eTable 1D).48 A double-blinded crossover study of umeclidinium
monotherapy in 350 patients with asthma (eTable 1D) found no
conclusive therapeutic beneﬁt in patients not receiving ICS.49
However, the results of a double-blinded crossover study of ICS
and umeclidinium combination therapy in 421 patients with
asthma (eTable 1D) showed improvements in trough FEV1 (26e55
mL) andmorning (15.9e22.9 L/min) and evening (16.2e28.8 L/min)
peak expiratory ﬂow compared with ICS alone.50
The tiotropium clinical trial program is currently the most
advanced, and tiotropium, delivered through a soft-mist inhaler,
has recently been incorporated into the Global Initiative for Asthma
2015 treatment guidelines as a recommended alternative therapy
at steps 4 and 5 in adult patients with a history of exacerbations.2
Data from 14 studies of tiotropium in asthma (eTable 1D) are
reviewed below in more detail.
Tiotropium
Tiotropium, a long-acting anticholinergic bronchodilator, is
currently approved by the US Food and Drug Administration for the
treatment of patients with chronic obstructive pulmonary dis-
ease.51,52 It also has recently been approved for use in the treatment
of asthma in the European Union and other countries worldwide.
Further, it is currently under evaluation in the United States and
other countries for the treatment of patients with asthma.
Early proof-of-concept studies in small numbers of patients
indicated that tiotropium, delivered through the Spiriva HandiHaler
device (Boehringer Ingelheim Pharmaceuticals, Inc, Ridgeﬁeld,
Connecticut), provides sustained bronchodilation and protection
against bronchoconstriction. A study by Fardon et al53 in 26 patients
with severe asthma demonstrated that once-daily tiotropium at 18
mg provided signiﬁcant improvements in lung function. Tiotropiumat 18 mg also was shown to provide signiﬁcant protection against
methacholine challenge in a study of 10 patients with asthma and
mild to moderate airway hyperresponsiveness.54 Sposato et al55
demonstrated that 18 mg of tiotropium provided greater protection
against methacholine-induced bronchoconstriction than ipra-
tropium bromide, with similar improvements in FEV1 compared
with oxitropium bromide, in a study of 44 patients with asthma.
In the large 3-way crossover TiotropiumBromide as an Alternative
to Increased InhaledCorticosteroid inPatients InadequatelyControlled
on a LowerDose of Inhaled Corticosteroid (TALC) study in 210 patients
with uncontrolled asthma (NCT00565266), once-daily tiotropium at
18 mg (through the SpirivaHandiHaler) signiﬁcantly improved asthma
symptoms (P < .001) and lung function (morning and evening peak
expiratory ﬂow, P< .001; FEV1, P¼ .004) comparedwith a doubling of
the ICS dose and was noninferior to salmeterol in patients with
symptomatic asthma.56 A prespeciﬁed analysis of the TALC study data
showed that a large number of patients who responded to treatment
with albuterol and had increased airway obstruction demonstrated
improved lung function after treatment with tiotropium.57
Recent studies in patients with symptomatic asthma have
evaluated the efﬁcacy of once-daily tiotropium delivered by the
Respimat Soft Mist inhaler (hereinafter referred to as tiotropium
Respimat; Boehringer Ingelheim, Ingelheim am Rhein, Germany;
Fig 1). The Respimat inhaler provides increased aerosol production
time compared with pressurized metered-dose inhalers and dry-
powder inhalers, which could beneﬁt patients with low inspira-
tory capacity or poor timing of inhalation to actuation.58
Phase 2 trials have examined the efﬁcacy and safety of different
doses anddosing regimens of tiotropiumRespimat. Tiotropiumat 10
and 5 mg as add-on to high-dose ICS plus LABA, taken each morning
(NCT00365560), signiﬁcantly improved peak FEV1 (P < .0001 for all
comparisons) and trough FEV1 (P < .0004 for all comparisons)
compared with placebo in 107 patients with severe symptomatic
asthma. Adverse events were balanced across treatment groups,
apart from dry mouth, which had a higher incidence in the 10-mg
tiotropium treatment group (6.8%; 1.9% in the 5-mg groupand1.0% in
the placebo group).59 Once-daily evening dosing of tiotropium at 5,
2.5, and 1.25 mg as add-on to medium-dose ICS in 149 patients with
moderate persistent asthma (NCT01233284) resulted in statistically
signiﬁcant improvements in lung function (peak FEV1 within 3
hours after the dose [peak FEV1(0e3h)], trough FEV1, FEV1 area under
the curve [AUC][0e3h], peak FVC[0e3h], trough FVC, and FVC
AUC[0e3h]), with the 5-mg dose associated with the greatest im-
provements in all measurements.60 Improvements in lung function
were found to be signiﬁcant and equally well sustained for once-
daily tiotropium at 5 mg (morning dosing) and twice daily at 2.5 mg
(morning and evening dosing) as add-on to medium-dose ICS in a
study of 94 patients with moderate symptomatic asthma
(NCT01152450).61 In a study of 388 patients with moderate asthma
with the B16-Arg/Arg genotype (NCT00350207), treatment with a
once-daily evening dose of 5 mg of tiotropium was found to be su-
perior tomatching placebo (P< .05) and as efﬁcacious as twice-daily
salmeterol (P ¼ .002) at maintaining improved lung function.62
Phase 3 trials have examined the efﬁcacy, safety, and tolerability
of tiotropium Respimat in patients across severities of symptomatic
asthma, as deﬁned by ICS dose. In 2 randomized, double-blinded,
48-week, parallel-group trials with identical designs
(NCT00772538 and NCT00776984), 912 patients with poorly
controlled asthma received 5 mg of tiotropium once daily or placebo
eachmorning as add-on to high-dose ICS plus LABA. Treatment with
5 mg of tiotropium signiﬁcantly improved peak and trough FEV1 (P
.01 for the 2 end points in the 2 trials) and increased the time to
the ﬁrst severe asthma exacerbation by 56 days, with a decrease of
21% in the risk of experiencing a severe exacerbation (pooled data,
P ¼ .03), compared with placebo.63 In 2 randomized, double-
blinded, double-dummy, parallel-group trials with identical design
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Figure 1. Overview of lung function results from clinical trials of tiotropium Respimat in adults with asthma: (A) peak forced expiratory volume in 1 second; (B) trough forced
expiratory volume in1 second; (C)morningpeakexpiratoryﬂow; (D) eveningpeakexpiratoryﬂow. Error bars represent SE. aMeasuredatweek8.59 bMeasuredatweek4.60 cMeasured
at the end of each 4-week treatment period.61 dMeasured atweek 16.62 eMeasured atweek 24.63 fPooled data; measured at week 24.64 gMeasured atweek 52.65 *P< .05; ***P< .001.
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symptomatic asthma received 5 or 2.5 mg of tiotropium, or salme-
terol or placebo, as add-on to medium-dose ICS. Because the results
were highly comparable between studies, the investigators pre-
sented pooled data. Signiﬁcant improvements in peak and trough
FEV1 were observed (P < .001 for all comparisons), with a larger
proportion of ACQ-7 responders observed after 24 weeks of treat-
ment with the tiotropium doses (5 mg, odds ratio 1.32, P ¼ .035; 2.5
mg, odds ratio 1.33, P ¼ .031), compared with placebo.64
Tiotropium Respimat was found to have safety and tolerability
thatwerecomparablewith thoseof placebo inall trials inwhich they
were assessed.59e65 In a long-term study of 5 or 2.5 mg of tiotropium
or placebo oncedailyas add-on tomedium-dose ICSwith orwithout
a LABA each evening in 285 Japanese patients (NCT01340209), the
safety and tolerability (primaryendpoint of the study) of tiotropium
were found to be comparable with those of placebo.65
The ﬁrst results from studies of tiotropium Respimat in adoles-
cents and children are available. A phase 2, incomplete-crossover,
dose-ranging study of 5, 2.5, and 1.25 mg of tiotropium as add-on
to medium-dose ICS with or without a leukotriene receptor antag-
onist was conducted in 105 adolescent patients 12 to 17 years old
with moderate symptomatic asthma (NCT01122680). Measure-
ments of peak FEV1(0e3h) (P ¼ .0004), trough FEV1 (P < .0001), and
FEV1 AUC(0e3h) (P ¼ .001) were signiﬁcantly improved after treat-
mentwith5mgof tiotropium.66 In a secondphase2 studyof identical
design in 101 children 6 to 11 years oldwithmoderate symptomatic
asthma (NCT01383499), signiﬁcant improvements in measure-
ments of peak FEV1(0e3h) (P< .001 for all comparisons), trough FEV1
(P < .005 for all comparisons), and FEV1 AUC(0e3h) (P < .005 for all
comparisons) were observed after treatment with all doses of tio-
tropium.67 As in the trials in adult patients, tiotropiumwas found to
have comparable safety and tolerability as placebo.66,67 Further
phase 2 and 3 studies of tiotropium as add-on to at least ICS in ad-
olescents and children as young as 1 year are in progress.Conclusions
There is currently an unmet need in the treatment of asthma,
with a signiﬁcant proportion of patients remaining symptomatic
despite treatment according to guidelines. Different additional
therapeutic options are undergoing development for use in the
treatment of asthma, including anti-IL agents, CRTH2 antagonists,
phosphodiesterase-4 inhibitors, and LAMAs.
The tiotropium clinical trial program is currently the most
advanced, with published data from different phase 2 and 3 ran-
domized clinical trials in patients with asthma. Data from studies in
adult and adolescent patients with asthma have shown that tio-
tropium is an efﬁcacious add-on to at least ICS maintenance ther-
apy, with comparable safety and tolerability as placebo. Tiotropium
could offer an alternative treatment option, particularly for patients
for whom current treatments are unsuitable or ineffective. In adult
patients with severe asthma and a history of exacerbations, tio-
tropium has recently been recommended as an alternative thera-
peutic option at Global Initiative for Asthma steps 4 and 5.2
It should be considered that clinical trial efﬁcacy is distinct from
real-life effectiveness. A recent retrospective study in 2,042 pa-
tients with asthma highlighted that primary care physicians in the
United Kingdom have been prescribing LAMAs for the treatment of
asthma since 2002, predominantly as add-on therapy in older pa-
tients with poorly controlled asthma despite good treatment
compliance, particularly in those who were current or former
smokers.68 In this real-life patient population, the addition of tio-
tropium, as 18 mg through the HandiHaler device (93%) or 5 mg
through the Respimat Soft Mist inhaler (7%), provided a signiﬁcant
decrease in the incidence of exacerbations and antibiotic pre-
scriptions for lower respiratory tract infections and a signiﬁcantincrease in asthma control during the following year. Additional
large studies of data from real-life asthma populations will help to
improve individualized patient care and will be useful to help
determine the position of tiotropium in relation to current asthma
treatment guidelines. Once fully indicated by regulatory authorities
and incorporated into asthma treatment guidelines across age
groups and disease severities, the use of tiotropium in the treat-
ment of asthma might become more widespread, given its avail-
ability in pharmacies and physicians’ familiarity with using it to
treat patients with chronic obstructive pulmonary disease.
Cost-effectiveness also is an important consideration in relation
to real-life utility of treatments and deciding their relative place in
therapeutic guidelines. This is particularly the case for biological
therapies that target speciﬁc cytokines, which might require
biomarker analyses to select the correct patients for treatment;
such biomarker analyses are not required before treatment with
tiotropium. In the ﬁrst analysis of the cost-effectiveness of tio-
tropium, Willson et al69 concluded that tiotropium provided a cost-
effective treatment option in adult patients with severe asthma, as
add-on to high-dose ICS plus LABA therapy. Further cost-
effectiveness analyses, across age ranges and severities of asthma,
could help to determine whether tiotropium add-on therapy pro-
vides an affordable treatment option that addresses the current
unmet need in asthma treatment.
The clinical development of other emerging therapeutic options
is less advanced compared with tiotropium; however, anti-IL
agents, CRTH2 antagonists, phosphodiesterase-4 inhibitors, and
other LAMAs also might provide additional options for the treat-
ment of asthma. The results of ongoing and future randomized
clinical trials of these and other agents will help to address the
current unmet need in patients with symptomatic asthma and to
determine where these emerging therapeutic options will ﬁt in
future asthma treatment guidelines.
Acknowledgments
The author takes full responsibility for the scope, direction,
content of, and editorial decisions relating to the article, was
involved at all stages of development, and has approved the
submitted article. Medical writing assistance, in the form of the
preparation and revision of the draft manuscript, was supported
ﬁnancially by Boehringer Ingelheim and provided by Lianne Young,
BSc, at Complete HealthVizion under the author’s conceptual di-
rection and based on feedback from the author.
Supplementary Data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.anai.2015.07.011.
References
[1] Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma (GINA)
Program. The global burden of asthma: executive summary of the GINA
Dissemination Committee report. Allergy. 2004;59:469e478.
[2] Global Initiative for Asthma. Global Strategy for Asthma Management and
Prevention. http://www.ginasthma.org/local/uploads/ﬁles/GINA_Report_
2015.pdf. Last updated April 2015. Accessed July 17, 2015.
[3] Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-deﬁned asthma
control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir
Crit Care Med. 2004;170:836e844.
[4] PartridgeMR,DalNegroRW,Olivieri D.Understanding patientswith asthmaand
COPD: insights from a European study. Prim Care Respir J. 2011;20:315e323.
[5] Demoly P, Paggiaro P, Plaza V, et al. Prevalence of asthma control among adults
in France, Germany, Italy, Spain and the UK. Eur Respir Rev. 2009;18:105e112.
[6] Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey
of patient-reported asthma control in Europe in the past 5 years. Eur Respir
Rev. 2012;21:66e74.
[7] Stanford RH, Gilsenan AW, Ziemiecki R, Zhou X, Lincourt WR, Ortega H.
Predictors of uncontrolled asthma in adult and pediatric patients: analysis of
the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS).
J Asthma. 2010;47:257e262.
R.A. McIvor / Ann Allergy Asthma Immunol 115 (2015) 265e271 271[8] Price D, Fletcher M, van der Molen T. Asthma control and management in
8,000 European patients: the REcognise Asthma and LInk to Symptoms and
Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.
[9] Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for
1160 sequelae of 289 diseases and injuries 1990e2010: a systematic analysis
for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163e2196.
[10] Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use, and
mortality: United States, 2005e2009. Natl Health Stat Report. 2011;32:1e14.
[11] Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K.
Effect of asthma exacerbations on health care costs among asthmatic patients
with moderate and severe persistent asthma. J Allergy Clin Immunol. 2012;
129:1229e1235.
[12] Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology
and the exacerbation-prone phenotype. Clin Exp Allergy. 2009;39:193e202.
[13] Sadatsafavi M, Rousseau R, Chen W, et al. The preventable burden of pro-
ductivity loss due to suboptimal asthma control: a population-based study.
Chest. 2014;145:787e793.
[14] Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of
asthma severity and control. Eur Respir J. 2008;32:545e554.
[15] Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled,
eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit
Care Med. 2011;184:1125e1132.
[16] Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with
elevated eosinophil levels. N Engl J Med. 2013;368:2455e2466.
[17] Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway
eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin
Immunol. 2013;132:1086e1096.
[18] Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizu-
mab, an antiinterleukin 5 receptor a monoclonal antibody, after acute
asthma. Am J Emerg Med. 2015;33:14e20.
[19] Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately
controlled asthma with elevated blood eosinophil counts: results from two
multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3
trials. Lancet Respir Med. 2015;3:355e366.
[20] BusseWW,HolgateS,KerwinE,etal.Randomized,double-blind,placebo-controlled
study of brodalumab, a human antieIL-17 receptor monoclonal antibody, in
moderate to severe asthma. Am J Respir Crit Care Med. 2013;188:1294e1302.
[21] Corren J, Lemanske RF Jr, Hanania NA, et al. Lebrikizumab treatment in adults
with asthma. N Engl J Med. 2011;365:1088e1098.
[22] Noonan M, Korenblat P, Mosesova S, et al. Dose-ranging study of leb-
rikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin
Immunol. 2013;132:567e574.
[23] Scheerens H, Arron JR, Zheng Y, et al. The effects of lebrikizumab in patients
with mild asthma following whole lung allergen challenge. Clin Exp Allergy.
2014;44:38e46.
[24] Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic
asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lan-
cet. 2012;380:651e659.
[25] Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of
refractory eosinophilic asthma. N Engl J Med. 2009;360:973e984.
[26] Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of
mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up
analysis. J Allergy Clin Immunol. 2014;133:921e923.
[27] Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for prednisone-
dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985e993.
[28] Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with
severe eosinophilic asthma. N Engl J Med. 2014;371:1198e1207.
[29] Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of
mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189e1197.
[30] Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and
efﬁcacy of mepolizumab in patients with moderate persistent asthma. Am J
Respir Crit Care Med. 2007;176:1062e1071.
[31] Pettipher R, Hunter MG, Perkins CM, et al. Heightened response of eosino-
philic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 2014;
69:1223e1232.
[32] Barnes N, Pavord I, Chuchalin A, et al. A randomized, double-blind, placebo-
controlled study of the CRTH2 antagonist OC000459 in moderate persistent
asthma. Clin Exp Allergy. 2012;42:38e48.
[33] SinghD, Cadden P, HunterM, et al. Inhibition of the asthmatic allergen challenge
response by the CRTH2 antagonist OC000459. Eur Respir J. 2013;41:46e52.
[34] Bateman ED, Izquierdo JL, Harnest U, et al. Efﬁcacy and safety of roﬂumilast in
the treatment of asthma. Ann Allergy Asthma Immunol. 2006;96:679e686.
[35] Bousquet J, Aubier M, Sastre J, et al. Comparison of roﬂumilast, an oral anti-
inﬂammatory, with beclomethasone dipropionate in the treatment of
persistent asthma. Allergy. 2006;61:72e78.
[36] van Schalkwyk E, Strydom K, Williams Z, et al. Roﬂumilast, an oral, once-daily
phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic re-
actions. J Allergy Clin Immunol. 2005;116:292e298.
[37] Louw C, Williams Z, Venter L, et al. Roﬂumilast, a phosphodiesterase 4 in-
hibitor, reduces airway hyperresponsiveness after allergen challenge. Respi-
ration. 2007;74:411e417.
[38] Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, et al. Roﬂumilast attenuates
allergen-induced inﬂammation in mild asthmatic subjects. Respir Res. 2011;
12:140.[39] Neville KA, Szeﬂer SJ, Abdel-Rahman SM, et al. Single-dose pharmacokinetics of
roﬂumilast in children and adolescents. J Clin Pharmacol. 2008;48:978e985.
[40] Restrepo RD. Use of inhaled anticholinergic agents in obstructive airway
disease. Respir Care. 2007;52:833e851.
[41] Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for
chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:297e304.
[42] Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in
the pathophysiology of asthma and COPD. Respir Res. 2006;7:73.
[43] Park HW. The role of tiotropium in the management of asthma. Asia Pac Al-
lergy. 2012;2:109e114.
[44] Westby MJ, Benson MK, Gibson PG. Anticholinergic agents for chronic asthma
in adults. Cochrane Database Syst Rev. 2004;3:CD003269.
[45] Novelli F, Malagrinò L, Dente FL, Paggiaro P. Efﬁcacy of anticholinergic drugs
in asthma. Expert Rev Respir Med. 2012;6:309e319.
[46] Price D, Fromer L, Kaplan A, van der Molen T, Román-Rodríguez M. Is there a
rationale and role for long-acting anticholinergic bronchodilators in asthma?
NPJ Prim Care Respir Med. 2014;24:14023.
[47] Wasilewski NV, Lougheed MD, Fisher JT. Changing face of b2-adrenergic and
muscarinic receptor therapies in asthma. Curr Opin Pharmacol. 2014;16:148e156.
[48] Hansel TT, Neighbour H, Erin EM, et al. Glycopyrrolate causes prolonged
bronchoprotection and bronchodilatation in patients with asthma. Chest.
2005;128:1974e1979.
[49] Lee LA, Briggs A, Edwards LD, Yang S, Pascoe S. A randomized, three-period
crossover study of umeclidinium as monotherapy in adult patients with
asthma. Respir Med. 2015;109:63e73.
[50] Lee LA, Yang S, Kerwin E, Trivedi R, Edwards LD, Pascoe S. The effect of ﬂu-
ticasone furoate/umeclidinium in adult patients with asthma: a randomized,
dose-ranging study. Respir Med. 2015;109:54e62.
[51] Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the
prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093e1103.
[52] Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic
obstructive pulmonary disease. N Engl J Med. 2008;359:1543e1554.
[53] Fardon T, Haggart K, Lee DKC, Lipworth BJ. A proof of concept study to evaluate
stepping down the dose of ﬂuticasone in combination with salmeterol and
tiotropium in severe persistent asthma. Respir Med. 2007;101:1218e1228.
[54] Terzano C, Petroianni A, Ricci A, D’Antoni L, Allegra L. Early protective effects
of tiotropium bromide in patients with airways hyperresponsiveness. Eur Rev
Med Pharmacol Sci. 2004;8:259e264.
[55] Sposato B, Calabrese A, Barzan R, Franco C. Comparison of the protective effect
amongst anticholinergic drugs on methacholine-induced bronchoconstriction
in asthma. J Asthma. 2008;45:397e401.
[56] Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy
for adults with uncontrolled asthma. N Engl J Med. 2010;363:1715e1726.
[57] Peters SP, Bleecker ER, Kunselman SJ, et al. Predictors of response to tio-
tropium versus salmeterol in asthmatic adults. J Allergy Clin Immunol. 2013;
132:1068e1074.e1.
[58] Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft
Mist Inhaler. Int J Pharm. 2004;283:1e9.
[59] Kerstjens HAM, Disse B, Schröder-Babo W, et al. Tiotropium improves lung
function in patients with severe uncontrolled asthma: a randomized
controlled trial. J Allergy Clin Immunol. 2011;128:308e314.
[60] Beeh KM, Moroni-Zentgraf P, Ablinger O, et al. Tiotropium Respimat in
asthma: a double-blind, randomised, dose-ranging study in adult patients
with moderate asthma. Respir Res. 2014;15:61.
[61] Timmer W, Moroni-Zentgraf P, Cornelissen P, Unseld A, Pizzichini E, Buhl R.
Once-daily tiotropium Respimat 5 mg is an efﬁcacious 24-hour bronchodi-
lator in adults with symptomatic asthma. Respir Med. 2015;109:329e338.
[62] Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM.
Tiotropium is noninferior to salmeterol in maintaining improved lung func-
tion in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011;128:
315e322.
[63] Kerstjens HAM, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled
with standard combination therapy. N Engl J Med. 2012;367:1198e1207.
[64] Kerstjens HAM, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-
on therapy to inhaled corticosteroids for patients with moderate symptom-
atic asthma: two replicate, double-blind, placebo-controlled, parallel-group,
active-comparator, randomised trials. Lancet Respir Med. 2015;3:367e376.
[65] Ohta K, Ichinose M, Tohda Y, et al. Long-term once-daily tiotropium
Respimat is well tolerated and maintains efﬁcacy over 52 weeks in patients
with symptomatic asthma in Japan: a randomised, placebo-controlled study.
PLoS One. 2015;10:e0124109.
[66] Vogelberg C, Engel M, Moroni-Zentgraf P, et al. Tiotropium in asthmatic ad-
olescents symptomatic despite inhaled corticosteroids: a randomised dose-
ranging study. Respir Med. 2014;108:1268e1276.
[67] Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, et al.
A randomised dose-ranging study of tiotropium Respimat in children with
symptomatic asthma despite inhaled corticosteroids. Respir Res. 2015;16:20.
[68] Price D, Kaplan A, Jones R, et al. Long-acting muscarinic antagonist use in
adults with asthma: real-life prescribing and outcomes of add-on therapy
with tiotropium bromide. J Asthma Allergy. 2015;8:1e13.
[69] Willson J, Bateman ED, Pavord I, Lloyd A, Krivasi T, Esser D. Cost effectiveness
of tiotropium in patients with asthma poorly controlled on inhaled gluco-
corticosteroids and long-acting b-agonists. Appl Health Econ Health Policy.
2014;12:447e459.
eTable 1
Summary of new therapeutic options in the treatment of asthma, with results published on PubMed: (A) anti-IL agents; (B) CRTH2 antagonists; (C) phosphodiesterase-4 inhibitors; (D) LAMAs
Study; trial number Treatment arm Phase Study design Patient population Background medicationa Key end points
A. Anti-IL agents
Laviolette et al, 20131;
NCT00659659
single dose of intravenous
benralizumab 1 mg/kg or placebo
(cohort 1) or 3 monthly
subcutaneous doses of
benralizumab 100 or 200 mg or
placebo (cohort 2)
1 randomized, double-blinded,
placebo-controlled study
27 patients 18e65 y old with
eosinophilic asthma
ND; regular asthma medication
maintained throughout study
adverse eventsb, airway
eosinophilsb, sputum, bone
marrow, and blood eosinophils
Nowak et al, 20152;
NCT00768079
single dose of intravenous
benralizumab 0.3 or 1 mg/kg or
placebo
2 randomized, double-blinded,
placebo-controlled, parallel-
group study
110 patients 18e60 y old with
acute eosinophilic asthma
ND; added to current standard-of-
care medication
proportion of patients with 1
exacerbation in placebo vs
combined benralizumab groupb,
time-weighted rate of
exacerbations, adverse events,
blood eosinophil counts, asthma
symptom changes, health care
resource use
Castro et al, 20113 infusions of reslizumab 3 mg/kg or
placebo (0.9% saline) every 4 wk
ND randomized, double-blinded,
placebo-controlled, 15-wk study
106 patients 18e75 y old with
severe eosinophilic asthma
high-dose ICS (ﬂuticasone 440 mg
BID) þ 1 other agent (including
SABA, LABA, leukotriene
antagonist, and cromolyn
sodium)
ACQ-7b, FEV1, % predicted FEV1,
FVC, blood and sputum
eosinophils, incidence of asthma
exacerbations
Castro et al, 20154;
NCT01287039 and
NCT01285323
intravenous reslizumab 3 mg/kg or
placebo every 4 wk
3 2 replicate randomized, double-
blinded, placebo-controlled,
parallel-group, 1-y studies
953 patients 12e75 y old with
blood eosinophils 400 cells/mL
and 1 exacerbation in previous
year
medium- to high-dose ICS
(ﬂuticasone 440 mg QD) 
another controller (LABA, oral
corticosteroids, leukotriene
modiﬁers, and cromolyn sodium)
annual frequency of exacerbationsb,
FEV1, ACQ-7, ASUI, rescue
medication use, blood
eosinophils, AQLQ, adverse
events
Wenzel et al, 20135;
NCT01312961
subcutaneous dupilumab 300 mg or
placebo once weekly
2 randomized, double-blinded,
placebo-controlled, parallel-
group, 12-wk study
104 patients 18e65 y old with
moderate to severe asthma and
elevated eosinophil levels
medium- to high-dose ICS þ LABA
(ﬂuticasone 250 or 500 mg and
salmeterol 50 mg BID or
equivalent) for 4 wk (LABA
discontinued and ICS tapered
during weeks 6e9)
incidence of asthma exacerbationsb,
time to asthma exacerbation,
FEV1, PEFAM, PEFPM, ACQ-5,
nocturnal wakening, rescue
medication use
Busse et al, 20136;
NCT01199289
subcutaneous brodalumab 140,
210, or 280 mg or placebo at day
1 and weeks 1, 2, 4, 6, 8, and 10
2a randomized, double-blinded,
placebo-controlled, dose-
ranging, 12-wk study
302 patients 18e65 y old with
moderate to severe asthma
stable-dose ICS (ﬂuticasone
200e1,000 mg QD or equivalent
for 3 mo before screening) for
30 d
ACQ-7b, FEV1, PEFAM, rescue
medication use, asthma symptom
scores, symptom-free days,
adverse events
Corren et al, 20117;
NCT00930163
subcutaneous lebrikizumab 250 mg
or placebo every 4 wk
2 randomized, double-blinded,
placebo-controlled, 24-wk study
219 adult patients with moderate
to severe symptomatic asthma
medium- to high-dose ICS
(ﬂuticasone 200 and 1,000 mg)
 LABA or leukotriene modiﬁers
FEV1b, incidence of asthma
exacerbations and severe
exacerbations, PEFAM, ACQ-5,
rescue medication use
Noonan et al, 20138;
NCT00971035
4 doses of subcutaneous
lebrikizumab 125, 250, or 500 mg
or placebo every 4 wk
2 randomized, double-blinded,
placebo-controlled, dose-
ranging, 12-wk study
212 patients 18e65 y old with
asthma not receiving ICS
treatment
none FEV1b, time to treatment failure,
PEFAM, PEF variability, reliever
medication use
Scheerens et al, 20149;
NCT00781443
4 doses of subcutaneous
lebrikizumab 5 mg/kg or placebo
every 4 wk
2 randomized, double-blinded,
parallel-group, placebo-
controlled, 12-wk study
29 patients 18e55 y old with mild
allergic asthma
intermittent short-acting inhaled
b2-adrenergic agonists only
allergen challengeb, adverse events,
serum biomarkers,
pharmacokinetics
Pavord et al, 201210;
NCT01000506
13 infusions of intravenous
mepolizumab 75, 250, or 750 mg
or placebo (100 mL 0.9% NaCl)
every 4 wk
1 randomized, double-blinded,
placebo-controlled, 52-wk study
621 patients 12e74 y old with
refractory eosinophilic asthma
ﬂuticasone 880 mg (or equivalent)
daily  maintenance oral
corticosteroids
incidence of asthma exacerbationsb,
blood and sputum eosinophils,
ACQ-6, quality of life
Haldar et al, 200911;
Haldar et al, 201412
12 infusions of intravenous
mepolizumab 750 mg or placebo
(150 mL 0.9% saline) every 4 wk
ND randomized, double-blinded,
placebo-controlled, parallel-
group, 50-wk study
61 patients 18 y old with
refractory eosinophilic asthma
high-dose corticosteroids incidence of severe asthma
exacerbationsb, ACQ-5, AQLQ,
FEV1, bronchodilator use, airway
hyperresponsiveness, blood and
sputum eosinophil counts
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Nair et al, 200913;
NCT00292877
5 infusions of intravenous
mepolizumab 750 mg or placebo
(normal saline diluent) every
4 wk
2 randomized, double-blinded,
placebo-controlled, parallel-
group, 26-wk study
20 adult patients with
corticosteroid-dependent
eosinophilic asthma
prednisone 5e25 mg and high-dose
ICS (ﬂuticasone 600e2,000 mg or
equivalent)
incidence of asthma exacerbationsb,
decrease in prednisone doseb,
ACQ, FEV1, sputum and blood
eosinophils
Ortega et al, 201414;
NCT01691521
intravenous mepolizumab 75 mg,
subcutaneous mepolizumab 100
mg, or placebo every 4 wk
3 randomized, double-blinded,
double-dummy, 32-wk study
576 patients 12e85 y old with
severe eosinophilic asthma
ﬂuticasone propionate 880 mg
(or equivalent) plus 3 mo of
treatment with an additional
controller
exacerbation rateb, spirometry,
hematology, ACQ-5, SGRQ,
adverse events, vital signs
Bel et al, 201415;
NCT01691508
subcutaneous mepolizumab 100
mg or placebo every 4 wk
3 randomized, double-blinded,
placebo-controlled, parallel-
group, 20-wk study
135 patients with severe
eosinophilic asthma
high-dose ICS (prednisone 5e35mg
or equivalent) plus additional
controller
decrease in ICS useb, exacerbation
rate, FEV1, ACQ-5, SGRQ, safety,
immunogenicity
Flood-Page et al, 200716 intravenous mepolizumab 250 or
750 mg or placebo every 4 wk
ND randomized, double-blinded,
placebo-controlled, 12-wk study
362 patients 18e55 y old with
moderate symptomatic asthma
ICS (beclomethasone 400e1,000
mg or equivalent)
PEFAMb, FEV1, asthma symptoms,
rescue medication use, quality of
life, incidence of asthma
exacerbations, blood and sputum
eosinophils
B. CRTH2 antagonists
Barnes et al, 201217;
NCT01057927
oral OC000459 200 mg BID or
placebo
2 randomized, double-blinded,
parallel-group, 4-wk study
132 steroid-free patients 18e55 y
old with moderate persistent
asthma
none FEV1b, PEF, asthma symptoms,
quality of life, rescue medication
use, sputum eosinophils, serum
IgE
Singh et al, 201318;
NCT01056692
oral OC000459 200 mg BID or
placebo
2 randomized, double-blinded,
placebo-controlled, 2-way
crossover, 16-d study
21 steroid-naive patients 18e45 y
old with allergic asthma
none allergen challengeb, sputum
eosinophils, FEV1
Pettipher et al, 201419;
NCT00890877
oral OC000459 25 or 200 mg QD,
100 mg BID, or placebo
2 randomized, dose-ﬁnding, double-
blinded parallel-group, 12-wk
study
519 patients 18e55 y old with mild
to moderate persistent asthma
none FEV1b, FVC, PEF, AQLQ, ACQ-7,
incidence of exacerbations and
respiratory tract infections,
rescue medication use, asthma
symptoms, adverse events
C. Phosphodiesterase-4 inhibitors
Louw et al, 200720 single dose of oral roﬂumilast 1,000
mg or placebo with 2- to 5-wk
washout between the 2 treatment
periods
ND randomized, double-blinded,
2-period, crossover study
13 patients 18e50 y old with mild
allergic asthma
none histamine challengeb, allergen
challengeb
van Schalkwyk et al, 200521 oral roﬂumilast 250 or 500 mg or
placebo QD for 7e10 d with
washout periods of 2e5 wk
between each treatment period
ND randomized, double-blinded,
placebo-controlled, 3-period
crossover study
23 patients 18e50 y old with mild
asthma
none allergen challengeb, FEV1
Gauvreau et al, 201122;
NCT01365533
oral roﬂumilast 500 mg or placebo
QD
2 randomized, double-blinded,
placebo-controlled, crossover,
14-d study
25 steroid-naive patients 18e54 y
old with mild allergic asthma
none allergen challengeb, FEV1,
methacholine challenge, sputum
eosinophils, pharmacokinetic
assessments
Bateman et al, 200623 oral roﬂumilast 100, 250, or 500 mg
QD
2/3 randomized, double-blinded,
parallel-group, 12-wk study
693 patients 15e70 y old with mild
to moderate asthma
none FEV1b, PEFAM, PEFPM, asthma
symptom scores, rescue
medication use, withdrawal
owing to lack of efﬁcacy
Bousquet et al, 200624 oral roﬂumilast 500 mg QD or
beclomethasone 200 mg BID
ND randomized, double-blinded,
double-dummy, noninferiority,
12-wk study
499 patients 12e70 y old with
persistent asthma
none FEV1b, FVC, PEFAM, PEFPM, asthma
symptom scores, rescue
medication use
Neville et al, 200825 single oral dose of roﬂumilast 100
mg in period 1 (3 d) and 250 mg in
period 2 (4 d) with washout
period of 14 d
ND open-label, crossover, 2-period,
ascending-dose study
25 children and adolescents with
mild to moderate asthma
none pharmacokinetic assessmentsb
D. LAMAs
Hansel et al, 200526 single dose of inhaled
glycopyrrolate 0.5, 1, or 2 mg,
ipratropium 0.5 mg, and placebo
with 7-d washout between
treatments
3 randomized, double-blinded,
placebo-controlled, 5-way
crossover study
10 patients 18e60 y old with mild
to moderate atopic asthma
none methacholine challengeb, adverse
events
(continued on next page)
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eTable 1 (continued )
Study; trial number Treatment arm Phase Study design Patient population Background medicationa Key end points
Lee et al, 201527; NCT01641692 3 of 8 treatments: inhaled
umeclidinium 15.6, 31.25, 62.5,
125, or 250 mg QD and
umeclidinium 15.6 or 31.25 mg
BID, or placebo for 14 d with 12-
to 14-d washout between
treatments
2 double-blinded, 3-period,
crossover, incomplete-block
study
350 patients 18 y old with asthma none trough FEV1b, PEFAM, PEFPM, rescue
medication use, 0- to 24-h
weighted mean FEV1, adverse
events, vital signs
Lee et al, 201528; NCT01573624 3 of 7 treatments: ﬂuticasone
furoate 100 mg alone QD,
ﬂuticasone furoate 100 mg QD þ
umeclidinium 15.6, 31.25, 62.5,
125, or 250 mg QD or vilanterol 25
mg QD for 14 d with 12- to 14-d
washout between treatments
2 double-blinded, 3-period,
crossover, incomplete-block
study
421 patients 18 y old with asthma ICS trough FEV1b, PEFAM, PEFPM, rescue
medication use, symptom-free
days, adverse events, vital signs
Fardon et al, 200729 inhaled ﬂuticasone 500 mg BID þ
salmeterol 100 mg BID þ
tiotropium 18 mg (HandiHaler)
QD or inhaled ﬂuticasone 500 mg
BID þ salmeterol 100 mg BID þ
placebo
ND randomized, double-blinded,
placebo-controlled, 4-wk
crossover study
26 patients 18 y old with severe
asthma
none FEV1, FVC, PEFAM, PEFPM, AQLQ,
body plethysmography
Terzano et al, 200430 single dose of inhaled tiotropium 18
mg (HandiHaler) or placebo
ND comparative, 3-challenge study
with 72-h washout between each
challenge
10 patients with asthma and
documented airway
hyperresponsiveness
ND methacholine challengeb
Sposato et al, 200831 single dose of inhaled ipratropium
40 mg, oxitropium 200 mg, or
tiotropium 18 mg (HandiHaler)
ND comparative study after 72-h
washout
44 patients with intermittent
bronchial asthma
none methacholine challengeb, FEV1
Peters et al, 201032; Peters et al,
201333; NCT00565266
inhaled tiotropium 18 mg
(HandiHaler) QD,
beclomethasone 160 mg BID
(ie, double run-in dose), or
salmeterol (Serevent Diskus;
GlaxoSmithKline, Research
Triangle Park, North Carolina) 50
mg BID
ND randomized, 3-way, double-
blinded, triple-dummy, 14-wk
crossover study
210 patients 18 y old with asthma ICS (beclomethasone 80 mg BID) PEFAMb, FEV1, number of asthma-
control days, asthma symptoms,
rescue bronchodilator use,
asthma exacerbations, use of
health care services, biomarkers
of airway inﬂammation, ACQ,
asthma symptoms, AQLQ,
adverse events
Kerstjens et al, 201134;
NCT00365560
inhaled tiotropium Respimat 10 or
5 mg or placebo Respimat QD
(morning dosing)
2 randomized, double-blinded,
24-wk crossover study
107 patients 18e75 y old with
severe persistent asthma
high-dose ICS (budesonide 800 mg
or equivalent) þ LABA
(theophylline, leukotriene
modiﬁers, and oral
glucocorticosteroids also
permitted in stable doses)
peak FEV1(0e3h)b, trough FEV1, peak
FVC, trough FVC, FEV1 AUC(0e3h),
FVC AUC(0e3h), PEFAM, PEFPM,
asthma symptoms, rescue
medication use, asthma
symptom-free days, mini-AQLQ,
adverse events, vital signs
Beeh et al, 201435;
NCT01233284
inhaled tiotropium Respimat 5, 2.5,
or 1.25 mg or placebo Respimat
QD (evening dosing)
2 randomized, double-blinded,
placebo-controlled, dose-
ranging, 4-way, 16-wk crossover
study
149 patients 18e75 y old with
moderate asthma
medium-dose ICS (budesonide
400e800 mg or equivalent)
peak FEV1(0e3h)b, trough FEV1, peak
FVC, trough FVC, FEV1 AUC(0e3h),
FVC AUC(0e3h), PEFAM, PEFPM,
ACQ-7, adverse events, vital signs
Timmer et al, 201536;
NCT01152450
inhaled tiotropium Respimat 5 mg
QD (evening, þ placebo Respimat
in morning), 2.5 mg BID (morning
and evening), or placebo
Respimat (morning and evening)
2 randomized, double-blinded,
placebo-controlled, 12-wk
crossover study
94 patients 18e75 y old with
moderate symptomatic asthma
medium-dose ICS (budesonide
400e800 mg or equivalent)
FEV1 AUC(0e24h)b, peak FEV1(0e24h),
trough FEV1, PEFAM, PEFPM, ACQ-
7, pharmacokinetic assessments,
adverse events
Bateman et al, 201137;
NCT00350207
inhaled tiotropium Respimat 5 mg
QD (evening), salmeterol HFA-
MDI 50 mg BID (morning and
evening), or matching placebo
2 randomized, double-blinded,
double-dummy, placebo-
controlled, parallel-group, 16-wk
study
388 patients 18e67 y old with
moderate asthma with B16-Arg/
Arg genotype
medium- to high-dose ICS
(budesonide 400e1,000 mg or
equivalent)
PEFAMb, PEFPM, FEV1, asthma
symptoms, rescue medication
use, asthma symptom-free days,
level of asthma control, adverse
events, vital signs, mini-AQLQ
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Kerstjens et al, 201238;
NCT00772538 and
NCT00776984
inhaled tiotropium Respimat 5 mg
or placebo Respimat QD (morning
dosing)
3 2 replicate randomized, double-
blinded, placebo-controlled,
parallel-group, 48-wk studies
912 patients 18e75 y old with
poorly controlled asthma
high-dose ICS (budesonide 800 mg
or equivalent) þ LABA (continued
use of stable-dose sustained-
ine, leukotriene
E, and oral
5 mg/d] was
peak FEV1(0e3h)b, trough FEV1b, time
to ﬁrst severe asthma
exacerbationb, 24-h FEV1
measurements, individual peak
and trough FEV1 and FVC
measurements, FEV1 AUC(0e3h),
FVC AUC(0e3h), time to the ﬁrst
Kerstjens et al, 201539;
NCT01172808 and
NCT01172821
inhaled tiotropium Respimat 5 or
2.5 mg QD (evening dosing),
salmeterol 50 mg HFA-MDI BID, or
matching placebo
3 2 replicate randomized, double-
blinded, double-dummy,
placebo-controlled, parallel-
group, 24-wk studies
2,100 patients 18e75 y old wit
moderate symptomatic asthm
Ohta et al, 201540;
NCT01340209
inhaled tiotropium Respimat 5 or
2.5 mg or placebo Respimat QD
(evening dosing)
3 randomized, double-blinded,
placebo-controlled, parallel-
group, 52-wk study
285 Japanese patients 18e75 y
with moderate symptomatic
asthma
Vogelberg et al, 201441;
NCT01122680
inhaled tiotropium Respimat 5, 2.5,
or 1.25 mg or placebo Respimat
QD (evening dosing)
2 randomized, double-blinded,
placebo-controlled, dose-
ranging, incomplete-crossover,
12-wk study
105 adolescents 12e17 y old w
moderate symptomatic asthm
Vogelberg et al, 201542;
NCT01383499
inhaled tiotropium Respimat 5, 2.5,
or 1.25 mg or placebo Respimat
QD (evening dosing)
2 randomized, double-blinded,
placebo-controlled, dose-
ranging, incomplete-crossover,
12-wk study
101 patients 6e11 y old with
moderate symptomatic asthm
Abbreviations: ACQ, Asthma Control Questionnaire; ACQ-5, 5-question Asthma Control Questionnaire; ACQ-6, 6-question Asthma Control Questionnai
Life Questionnaire; ASUI, Asthma Symptom Utility Index; AUC(0e3h), area under the curve within 3 hours after dose; BID, twice daily; CRTH2, chemo
phocytes; FEF25e75%, forced expiratory ﬂow between 25% and 75%; FEV1, forced expiratory volume in 1 second; FVC(0e3h), forced vital capacity with
metered-dose inhaler; ICS, inhaled corticosteroids; IgE, immunoglobulin E; IL, interleukin; LABA, long-acting b2-agonist; LAMA, long-actingmuscarinic
of Life Questionnaire; peak FEV1(0e3h), peak forced expiratory volume in 1 second within 3 hours after dose; PEF, peak expiratory ﬂow; PEFAM, morni
SABA, short-acting b2-agonist; SGRQ, St George’s Respiratory Questionnaire.
aExcluding rescue medication.
bPrimary end point.release theophyll
modiﬁers, anti-Ig
glucocorticoids [
permitted)episode of asthma worsening,
PEFAM, PEFPM, ACQ-7, AQLQ,
adverse events, vital signs
h
a
medium-dose ICS (budesonide
400e800 mg or equivalent)
peak FEV1(0e3h)b, trough FEV1b,
ACQ-7 responder rateb, peak
FVC(0e3h), trough FVC, PEFAM,
PEFPM, AQLQ, time to ﬁrst severe
exacerbation, time to ﬁrst
episode of asthma worsening, 24-
h FEV1 and FVC, adverse events
old medium-dose ICS (budesonide
400e800 mg or equivalent) 
LABA
adverse eventsb, vital signsb, trough
FEV1, trough FVC, trough PEF,
ACQ-7 responder rate, adverse
events
ith
a
medium-dose ICS  leukotriene
receptor antagonists
peak FEV1(0e3h)b, trough FEV1, FEV1
AUC(0e3h), PEFAM, PEFPM, ACQ-7,
adverse events, vital signs
a
medium-dose ICS (budesonide
200e400 mg or equivalent) 
leukotriene receptor antagonists
peak FEV1(0e3h)b, trough FEV1, FEV1
AUC(0e3h), peak FVC(0e3h), trough
FVC, FVC AUC(0e3h), PEFAM, PEFPM,
individual FEV1 measurements,
FEF25e75%, ACQ-7, PAQLQ(S),
adverse events
re; ACQ-7, 7-question Asthma Control Questionnaire; AQLQ, Asthma Quality of
attractant receptor-homologous molecule expressed on T-helper type 2 lym-
in 3 hours after dose; FVC, forced vital capacity; HFA-MDI, hydroﬂuoroalkane
antagonist; ND, not deﬁned; PAQLQ(S), Standardised Paediatric AsthmaQuality
ng peak expiratory ﬂow; PEFPM, evening peak expiratory ﬂow; QD, once daily;
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